SNHG15 knockdown inhibits diabetic nephropathy progression in pediatric patients by regulating the miR-141/ICAM-1 axis in vitro

Running header: Regulatory mechanism of SNHG15 on DN

Jiewei Liu1#, MM; Dongliang Cai2#, MM; Ying Wang1, MM; Yanhong Zou1, MM; Tana Zhao1*, MM

1 The Second Department of Pediatrics, The First Affiliated Hospital of Jiamusi University, No. 238, Dexiang Street, Jiamusi City, Heilongjiang Province, 154002, China.

2 Department of Geratology, The First Affiliated Hospital of Jiamusi University, No. 238, Dexiang Street, Jiamusi City, Heilongjiang Province, 154002, China.

# Jiewei Liu and Dongliang Cai contributed equally to this work.

*Corresponding author: Tana Zhao

Address: The Second Department of Pediatrics, The First Affiliated Hospital of Jiamusi University, No. 238, Dexiang Street, Jiamusi City, Heilongjiang Province, 154002, China.

Phone number: +86-18604549880

Email: zhaotana1680@163.com
Abstract

Long non-coding RNAs (lncRNAs) are confirmed to be involved in modulating diabetic nephropathy (DN). This study is aimed to explore the regulatory mechanism of lncRNA small nucleolar RNA host gene 15 (SNHG15) on pediatric DN. Human glomerular mesangial cells (HGMCs) were exposed to high glucose (HG) to produce an in vitro model. The results showed that SNHG15 was remarkably up-regulated in pediatric DN tissues and HG-induced HGMCs. Functional experiments indicated that both silencing of SNHG15 and overexpression of miR-141 elevated the cell viability, and suppressed the inflammation in HG-induced HGMCs. SNHG15 was identified to be a lncRNA that could bind to miR-141, and ICAM-1 was a downstream target gene of miR-141. Both the low expression of miR-141 and high expression of ICAM-1 reversed the inhibiting effect of SNHG15 knockdown on inflammatory response, and the promoting effect on cell viability. To conclude, our study revealed that silencing of SNHG15 ameliorated the malignant behaviors of pediatric DN via modulating the miR-141/ICAM-1 axis in vitro.

Keywords: diabetic nephropathy; lncRNA SNHG15; miR-141; ICAM-1; high-glucose
Introduction

Diabetic nephropathy (DN) is a main and serious complication of diabetes mellitus (DM) [1, 2]. The increasing rates of childhood obesity worldwide have been reported to be strongly associated with the rising prevalence of DM [3]. In especial, microalbuminuria (MA), or incipient DN is the most common abnormal finding in diabetic children and adolescents, whereas overt proteinuria is found in less than 1-1.5% of pediatric patients [4, 5]. The pathological features of DN are in many ways and inflammation is one of the most common pathological-factors [6, 7]. Numerous researches have indicated that inflammation response in renal facilitates the development of DN [8, 9]. Although various therapies such as controlling blood glucose [10] and inflammation [11] for treating DN have been improved, the therapeutic effects remain disillusionary. Therefore, further molecular research on the potential mechanism of DN is urgent to be solved to develop promising therapeutic targets in DN.

Some long non coding RNAs (lncRNAs) are widely known to be participated in modulating cellular processes, including release of inflammatory cytokines in an in vitro model of DN [12-14]. Zhang et al. have disclosed that knockdown of IncRNA Rpph1 restrains inflammatory cytokines release in mice mesangial cells (MMCs) [12]. Peng et al. have uncovered the decreased inflammatory-factors levels of mesangial cells (MCs) were positively correlated with IncRNA NONHSAG053901 down-regulation [13]. Ma et al. have illustrated that inflammatory reaction in HG-induced MMCs was suppressed by silencing of IncRNA NEAT1 [14]. The above researches indicated that some lncRNAs serve as a proinflammmatory-factor role in cells. Interestingly, small nucleolar RNA host gene 15 (SNHG15) has been reported to serve as a morbigenous lncRNA in human cancers, such as lung cancer [15], breast
cancer [16], ovarian cancer [17] and prostate cancer [18]. More importantly, also as a member of SNHG family, SNHG16 has been confirmed to play a promoting role in the proliferation of HG-induced MMCs and fibrosis of DN tissues [19]. However, whether SNHG15 is involved in modulating inflammatory response and the development of DN remains unclear.

Increasing researches have been demonstrated that microRNAs (miRNAs) exhibit their suppressive roles in DN progression or cell inflammation [20-22]. For instance, miR-181a overexpression declines concentrations of IL-6 and IL-1β in mesangial cells, eventually alleviating the inflammatory response of DN [20]. MiR-218 up-regulation visibly restrains IL-6, IL-1β and TNF-α levels of murine podocyte cells [21]. Overexpression of miR-485 dampens the inflammation and proliferation of mesangial cells in an in vitro model of DN [22]. Of note, miR-141 has also been reported to act as a suppressor on DN in vitro [19, 23]. Recent studies have revealed that the increased miR-141 expression significantly attenuates renal fibrosis [19, 23] and cell proliferation [19]. However, the effect of miR-141 on inflammation of MCs and the regulatory mechanism between miR-141 and SNHG15 have not been fully elucidated.

In this study, we investigated the effects of lncRNA SNHG15 on the viability and inflammation of HGMCs, and explored the regulatory mechanisms between SNHG15 and miR-141/ICAM-1 on pediatric DN. This study highlighted the molecular mechanism of how SNHG15 mediates the progression of DN in vitro.

Methods

Tissues Collection

From 2017 to 2018, totally 15 pediatric DN patients without other complications were selected in our hospital. DN patients had not received treatment
within 3 months prior to admission. Simultaneously, 20 healthy children undergone a physical examination were recruited as controls. The pathological kidney tissues of the patients and the normal kidney tissues of the healthy children were obtained by biopsy. Written informed consent was obtained for each patient. This study obtained the approval of the Ethics Committee in our hospital.

*Cell culture, grouping and transfection*

Human glomerular mesangial cells (HGMCs) were purchased from Xinyu Biotech, Ltd (Shanghai, China) and cultured in DMEM containing 10% fetal bovine serum (FBS) at 37°C. Then, HGMCs were further divided into two groups: the high glucose (HG, 33.3 mM glucose) group and normal glucose (NG, 5.5 mM glucose) group.

ShRNA-negative control (sh-NC) and shRNA-SNHG15 (sh-SNHG15) were procured from Sangon Biotech, Inc (Shanghai, China). MiR-141 inhibitor and its negative control inhibitor NC, miR-141 mimics and its negative control miR-NC, overexpression-SNHG15 (oe-SNHG15), overexpression-ICAM-1 (oe-ICAM-1) and their negative control pcDNA3.1, were all procured from Ribo Biotech, Ltd (Guangzhou, China). HG-induced HGMCs were transfected with the aforementioned agents using Lipofectamine RNAiMAX kit (Invitrogen, Carlsbad, CA, USA) for 48 h. Subsequently, the cells were harvested to perform the following experiments.

*Quantitative reverse-transcription PCR (qRT-PCR)*

Following the manufacturer's instructions, total RNA from pediatric DN tissues or HG-induced HGMCs was extracted using a TRIzol kit (Invitrogen, Inc.). The extracted RNA was reverse transcribed into cDNA using the GoScript reverse transcription system (Promega, Madison, WI, USA) and then subjected to qRT-PCR analyses. The thermocycling conditions were: 95°C for 10 min, followed by 40 cycles
of 95°C for 10 sec, 60°C for 20 sec and 72°C for 34 sec. GAPDH or U6 was used as the internal reference. Gene expression was quantified using the \(2^{\Delta\Delta Ct}\) method.

**MTT assay**

The HG-induced HGMCs cells were seeded into a 96-well plate with \(2 \times 10^5\) cells per well at 37°C. After incubation for 24 h, 20 µl MTT (GENECHEM, Inc, Shanghai, China) was added to each well to incubate for another 2 h at 37°C. The viability (OD450) was analyzed using a Multiskan Spectrum microplate reader (Thermo Fisher Scientific, Waltham, MA, USA).

**Enzyme-linked immunosorbent assay (ELISA)**

The levels of the inflammatory cytokines (TNF-α, IL-1β and IL-6) in HG-induced HGMCs were measured using a specific ELISA kit (Multisciences Biotech, Ltd., Hangzhou, China) in accordance with the manufacturer protocol. A Multiskan Spectrum microplate reader (Thermo Fisher Scientific) was used to determine the absorbance at 450 nm.

**Dual luciferase reporter (DLR) assay**

SNHG15 with WT or MUT miR-141-binding sites were fused to the pGL3 vector. The 3’-UTR of ICAM-1 containing the predicted miR-141 targeting site (WT) and MUT ICAM-1 were cloned into the pGL3 vector. Wild-type/mutant-type vector and miR-141 mimics/miR-NC were co-transfected into HGMCs for 48 h at 37°C. The relative luciferase activity was detected using a Dual-Luciferase Reporter Assay System (Promega).

**Western blot analysis**

The proteins from HG-induced HGMCs were extracted using RIPA buffer containing protease inhibitor, followed by detecting the protein concentrations by a BCA Protein Assay Kit (Abcam). Then, proteins were separated by 10% SDS-PAGE
and transferred into PVDF membrane. At room temperature, the blocking was performed using 5% bovine serum albumin (BSA). After that, the membrane was incubated with primary antibodies against ICAM-1 (1:1,000; Abcam) and β-actin (1:1,000; Abcam) for overnight at 4°C. Then, tris-buffered saline Tween-20 (TBST) was used to wash the membrane for three times. Subsequently, at room temperature, the secondary antibody HRP-conjugated anti-mice IgG (1:5,000; Santa Cruz, Waltham, MA, USA) was added to incubate for 1 h. β-actin was used as the internal reference. The membrane was developed by Chemiluminescence reagents (Thermo Fisher Scientific) under Gel-Pro analyzer (version 4.0, USA).

**Statistical analysis**

SPSS software (version 20.0, USA) was used to perform statistical analyses. Data were expressed as the mean ± standard deviation. Student t-test was utilized to assess the differences between two groups, whereas one-way ANOVA was used to evaluate the differences among multiple groups. After ANOVA analysis, the pairwise comparison was performed using Tukey's multiple comparisons test. P-value less than 0.05 indicated a statistically significant difference. All experiments were conducted in triplicate in at least three independent experiments.

**Results**

*Release of inflammatory cytokines in HG-induced HGMCs is restrained by SNHG15 knockdown*

SNHG15 expression in pediatric DN and normal tissues was detected by qRT-PCR. The results uncovered that the expression of SNHG1 in pediatric DN tissues was up-regulated in contrast to that in normal tissues (Fig. 1A, \( P < 0.001 \)). Meanwhile, we found that SNHG15 expression was also increased in HG-induced HGMCs compared with the NG controls. (Fig. 1B, \( P < 0.001 \)). After transfection of
sh-SNHG15/NC or pDNA3.1/oe-SNHG15 into HG-stimulated HGMCs, the efficiency of transfection was detected. The results of qRT-PCR revealed that SNHG15 expression was visibly down-regulated by sh-SNHG15 and up-regulated by oe-SNHG15 (Fig. 1C, \( P < 0.001 \)). As shown in Fig. 1D, the viability of HG-induced HGMCs was promoted by transfection of sh-SNHG15, whereas was inhibited by transfection of oe-SNHG15 (\( P < 0.001 \)). Interestingly, the opposite results were obtained in the levels of inflammatory cytokines. Through ELISA, we discovered that SNHG15 knockdown significantly decreased and SNHG15 overexpression elevated the levels of IL-6, IL-1β and TNF-α (Fig. 1E, \( P < 0.001 \)). These results indicated that SNHG15 might be a proinflammatory factor in DN.

*LncRNA SNHG15 targets miR-141*

Through Starbase software, a potential binding site between lncRNA SNHG15 and miR-141 were depicted (Fig. 2A). DLR assay further demonstrated that in comparison to the SNHG15-WT/miR-NC group, the luciferase activity in the SNHG15-WT/miR-141 mimic group was obviously diminished (Fig. 2B, \( P < 0.001 \)). Next, we utilized qRT-PCR to detect the expression of miR-141 in pediatric DN tissues and the results presented that miR-141 expression was down-regulated in pediatric DN tissues in contrast to the normal tissues (Fig. 2C, \( P < 0.001 \)). Pearson’s correlation analysis uncovered that there was an inverse correlation between the expression of SNHG15 and miR-141 in pediatric DN tissues (Fig. 2D; \( P < 0.0001 \), \( R^2 = 0.701 \)). To further verify the correlation between SNHG15 and miR-141, miR-141 expression was detected after transfection of sh-SNHG15/NC or pDNA3.1/oe-SNHG15 into HG-stimulated HGMCs. The results of qRT-PCR displayed that miR-141 expression was up-regulated by SNHG15 knockdown and was down-regulated by SNHG15 overexpression (Fig. 2E, \( P < 0.001 \)). The above data
implied that miR-141 was the target of SNHG15 and was negatively modulated by SNHG1.

*Overexpression of miR-141 declines the levels of inflammatory factors in HG-induced HGMCS*

To further explore the biological function of miR-141 on pediatric DN in vitro, we first detected the expression of miR-141 in HG-induced HGMCS. The results of qRT-PCR demonstrated that miR-141 expression was dramatically reduced in HG-stimulated HGMCS in comparison to that of NG-treated cells (Fig. 3A, \( P < 0.001 \)). Also, the efficiency of transfection was detected by qRT-PCR after transfection of miR-141 mimics/inhibitor into HG-stimulated HGMCS. We discovered that miR-141 expression was elevated by transfection of miR-141 mimics, whereas was declined by transfection of miR-141 inhibitor (Fig. 3B, \( P < 0.001 \)), suggesting that miR-141 mimics/inhibitor was transfected into HG-induced HGMCS successfully. MTT assay displayed that transfection of miR-141 mimics significantly promoted cell viability while the viability of HG-induced HGMCS was suppressed by miR-141 inhibitor (Fig. 3C, \( P < 0.001 \)). In addition, ELISA revealed that the levels of IL-6, IL-1β and TNF-α were decreased by miR-141 overexpression and increased by miR-141 downregulation (Fig. 3D, \( P < 0.001 \)). The above results indicated that overexpression of miR-141 could inhibit the viability and release of inflammatory factors in HG-induced HGMCS.

*MiR-141 targets ICAM-1*

We predicted the potential binding site between ICAM-1 and miR-141 based on Targetscan software (Fig. 4A). In contrast to the ICAM-1 WT/miR-NC group, a decreased luciferase activity in the ICAM-1-WT/miR-141 mimic group was exhibited by DLR assay (Fig. 4B, \( P < 0.001 \)). To further verify the correlation between ICAM-1
and miR-141, western blot was utilized to detect the protein level of ICAM-1 after transfection of miR-141 mimics/ inhibitor into HG-stimulated HGMCs. We found that ICAM-1 protein level was visibly inhibited by miR-141 mimics, whilst was elevated by miR-141 inhibitor (Fig. 4C, \( P < 0.001 \)). The results suggested that ICAM-1 was the target gene of miR-141.

**MiR-141 diminishes the levels of inflammatory factors in HG-induced HGMCs through regulating ICAM-1**

qRT-PCR was utilized to detect ICAM-1 expression of HG-induced HGMCs and the results demonstrated that the expression of ICAM-1 was distinctly up-regulated in the HG group by contrast to the NG group (Fig. 5A, \( P < 0.001 \)). Then based on western blot analysis, we further determine the protein level of ICAM-1. The results revealed that up-regulation of ICAM-1 reversed the inhibitory effect of miR-141 mimics on ICAM-1 protein level (Fig. 5B, \( P < 0.001 \)). Similarly, MTT assay and ELISA respectively illustrated that overexpression of ICAM-1 reversed the promoting effects of miR-141 mimics on cell viability and the suppressive effect on the levels of IL-6, IL-1β and TNF-α (Fig. 5C-D, \( P < 0.001 \)). We speculated that the effects of miR-141 on cell viability and release of inflammatory factors were achieved through regulating ICAM-1.

**SNHG15 knockdown promotes the viability and inhibits inflammatory response of HG-induced HGMCs by regulating miR-141/ICAM-1**

To investigate the interactions among SNHG15, miR-141 and ICAM-1, the feedback verification experiments were performed. The results of western blot presented that the protein level of ICAM-1 was declined by silencing of SNHG15. However, both down-regulation of miR-141 (\( P < 0.01 \)) and up-regulation of ICAM-1 (\( P < 0.001 \)) reversed the suppressive effect of SNHG15 knockdown on ICAM-1.
protein level (Fig. 6A, \( P < 0.001 \)). In addition, MTT assay and ELISA respectively uncovered that the low expression of miR-141 and high expression of ICAM-1 reversed the promoting effect of SNHG15 knockdown on cell viability and the inhibitory effects on levels of IL-6, IL-1β and TNF-α (Fig. 6B-C, \( P < 0.05 \)). The above data indicated that SNHG15 knockdown might elevate the viability and suppress inflammatory response of HG-induced HGMCs by regulating the miR-141/ICAM-1 axis.

**Discussion**

DN is one of the most renal diseases caused by hyperglycemia and inflammation, usually leading to serious damage of renal [24-26]. As previous studies mentioned, HG can damage cells by affecting diverse cellular processes, such as mitochondrial injury, oxidative damage, and inflammation [27-29]. Because the pathological changes of HGMCs induced by HG are similar with the pathogenesis of DN, HG-induced HGMCs are commonly used to simulate the DN in vitro [27]. Therefore, an in vitro model of DN was established in HGMCs by HG treatment in this study. Researchers have displayed that lncRNAs play important roles in DN in vivo and/or in vitro [30-32]. Cheng et al. have uncovered that Dlx6os1 is significantly expressed in MCs under HG conditions by contrast to that in NG conditions [30]. Li et al. have illustrated that the increased MEG3 expression is observed in HG-stimulated MCs [31]. Also, Yang et al. have presented that XIST expression is up-regulated in DN tissues and HG-induced HK-2 cells [32]. Consistent with the above results, we disclosed that high expression of SNHG15 was exhibited in pediatric DN tissues and HG-induced HGMCs. Therefore, our data implied that SNHG15 might be a pathogenic lncRNA in DN.

Previous researches have been reported that aberrant expression of some
IncRNAs is involved in modulating release of inflammatory factors in an in vitro model of DN [13, 14, 33]. For instance, silencing of Blnc1 visibly inhibited secretion of IL-6, IL-1β and TNF-α in HG-induced HK-2 cells [33]. In HG-induced MMCs, the expression of inflammatory cytokines was dampened by NEAT1 knockdown [14]. The levels of IL-6 and IL-1β in HG-treated MCs were restrained by down-regulation of NONHSAG053901 and elevated by up-regulation of NONHSAG053901 [13]. In this study, We discovered that SNHG15 knockdown significantly declined the levels of IL-6, IL-1β and TNF-α, whilst overexpression of SNHG15 could promote secretion of IL-6, IL-1β and TNF-α in HG-induced HGMCs. The results indicated that silencing of SNHG15 could dampen the inflammatory response of DN in vitro. Similar to our results, a recent study has been illustrated that SNHG15 interference visibly suppresses the levels of inflammatory cytokines in mouse RAW264.7 cells [34]. However, this previous study only explored the effect of SNHG15 on inflammatory response in an in vitro model of spinal tuberculosis. Our results further verified that SNHG15 knockdown restrained inflammatory response of DN in vitro. Besides, in our research, we also found that the viability of HG-induced HGMCs was facilitated by transfection of sh-SNHG15 and suppressed by transfection of oe-SNHG15. Therefore, we speculated that SNHG15 knockdown inhibited the development of DN in vitro. However, the expression fold of SNHG15 was not consistent with the change folds of different cell processes, such as cell viability and inflammation. Because the molecular mechanism is complex in cell processes, the effect of SNHG15 may be influenced by other regulatory factors, especially for the adverse changes. Numerous studies have been revealed that miRNAs serve as suppressors in the levels of inflammatory factors of multiple diseases [35-38], including in DN in vitro [20-22]. Zha et al. have demonstrated that the decreased expression of miR-181a dramatically
elevates the levels of inflammatory factors in HG-treated RAW264.7 cells, while the expression of inflammatory factors is inhibited by miR-181a overexpression [20]. Li et al. have disclosed that miR-218 expression is down-regulated in DN tissues and HG-induced murine podocyte cells, whereas overexpression of miR-218 attenuates the inflammatory damage to HG-induced murine podocyte cells [21]. A study conducted by Wu et al. has also uncovered that a low expression of miR-485 is observed in HG-treated human mesangial cells, while miR-485 up-regulation dampens the inflammation of HG-induced cells [22]. Consistent with the above researches, our study presented that miR-141 expression was also down-regulated in pediatric DN tissues and HG-induced HGMCs. IL-6, IL-1β and TNF-α levels were all suppressed by miR-141 overexpression. Cell viability promoted by miR-141 overexpression was also verified. At the same time, a negatively regulatory relationship between SNHG15 and miR-141 was confirmed. We conjectured that silencing of SNHG15 might mitigate DN progression in vitro through regulating miR-141. The feedback verification experiment between SNHG15 and miR-141 was performed to further verify this assumption. The relevant experiment demonstrated that miR-141 down-regulation reversed the inhibiting effect of SNHG15 knockdown on inflammation and the promoting effect on cell viability. The above results indicated that knockdown of SNHG15 alleviated inflammatory response of DN in vitro through regulating miR-141.

Intercellular adhesion molecule-1 (ICAM-1) belonging to immunoglobulin superfamily is an inflammatory sign and contributes to the progression of DN [39-41]. ICAM-1 has been confirmed to distinctly up-regulate in DN in vitro [42-45]. In our study, we also found in HG-induced HGMCs, the elevated expression of ICAM-1 was detected, which was consistent with the previous studies [46, 47]. The results implied
that ICAM-1 might be a promotor in DN. At the same time, ICAM-1 was identified to be a target gene of miR-141 and was negatively regulated by miR-141. We conjectured that miR-141 was involved in regulating the levels of inflammatory factors via regulating ICAM-1. Our feedback verification experiments that overexpression of ICAM-1 reversed the suppressive effect of miR-141 on IL-6, IL-1β and TNF-α levels further confirmed this hypothesis. In line with our results, a recent study has reported that miR-141 restrains inflammation caused by myocardial ischemia-reperfusion injury through negative regulation of ICAM-1 [48]. Additionally, in the above studies, we have confirmed that the interaction between SNHG15 and miR-141 on DN in vitro. We further conjectured that SNHG15 knockdown attenuated the inflammation of DN through modulating the miR-141/ICAM-1 axis. The feedback verification experiments between SNHG15 and ICAM-1 uncovered that the inhibitory effects of SNHG15 on the levels of inflammatory cytokines were dramatically reversed by ICAM-1 overexpression. Taken together, all the data in our study suggested that SNHG15 knockdown dampened inflammatory response of HG-induced HGMCs by regulating the miR-141/ICAM-1 axis. Additionally, ICAM-1 has been reported to interact with many signaling pathways in human diseases, such as ICAM-1-PI3K/Akt/GSK-3β/GATA-6 pathway in atherosclerosis [49], ICAM-1-IL-6/AKT/STAT3/NF-κB pathway in chronic obstructive pulmonary disease [50], and ICAM-1-PGE2/EP1 pathway in oral cancer [51]. Notably, ICAM-1 can interact with the SphK1-S1P pathway [52] and NF-κB pathway [53] in DN. We speculated that the SNHG15/miR-141/ICAM-1 axis may also be involved in the progression of DN by regulating these signaling pathways. Further researches on relevant mechanisms still need to be studied.

In summary, the current study uncovered SNHG15, which acts as an endogenous
sponge of miR-141 to affect the development of pediatric DN in vitro. Up-regulation of miR-141 down-regulates ICAM-1, inhibiting the inflammatory reaction of pediatric DN in vitro. This study reveals that the SNHG15/miR-141/ICAM-1 axis is essential in pediatric DN progression, pointing to SNHG15 may be a new therapeutic target for DN. However, this study did not confirm the detailed mechanism among them in vivo, which may be a limitation of the present study. Further experiments will be performed to elucidate these issues in the future.

**Ethics approval and consent to participate:** This study was conducted after obtaining The First Affiliated Hospital of Jiamusi University’s ethical committee approval.

**Data Availability Statement**

All data can be obtained by contacting the corresponding author.

**Funding:** Basic scientific research project of provincial undergraduate universities in heilongjiang province in 2018 (2018-KYYWF-0962)

**Authors’ contributions:** JWL and DLC designed and analyzed the experiment, and was a major contributor in writing the manuscript. YW, YHZ and TNZ performed the experiment. All authors have read and approved the final manuscript.

**References:**

1. Elmarakby, A.A. and J.C. Sullivan, *Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy*. Cardiovasc Ther, 2012. 30(1): p. 49-59.
2. Kim, S.Y., T.D. Jeong, W. Lee, S. Chun, S. Sunwoo, S.B. Kim, et al., *Plasma Neutrophil Gelatinase-Associated Lipocalin as a Marker of Tubular Damage in Diabetic Nephropathy*. Ann Lab Med, 2018. 38(6): p. 524-529.
3. Gungor, N., T. Hannon, I. Libman, F. Bacha, and S. Arslanian, *Type 2 diabetes mellitus in youth: the complete picture to date*. Pediatr Clin North Am, 2005. 52(6): p. 1579-609.
4. Schultz, C.J., T. Konopelska-Bahu, R.N. Dalton, T.A. Carroll, I. Stratton, E.A. Gale, et al., *Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study*. Oxford Regional Prospective Study
16

Group. Diabetes Care, 1999. 22(3): p. 495-502.

5. Mortensen, H.B., K. Marinelli, K. Norgaard, K. Main, K.W. Kastrup, K.K. Ibsen, et al., A nation-wide cross-sectional study of urinary albumin excretion rate, arterial blood pressure and blood glucose control in Danish children with type 1 diabetes mellitus. Danish Study Group of Diabetes in Childhood. Diabet Med, 1990. 7(10): p. 887-97.

6. Tufro, A. and D. Veron, VEGF and podocytes in diabetic nephropathy. Semin Nephrol, 2012. 32(4): p. 385-93.

7. Jeong, K.H., T.W. Lee, C.G. Ihm, S.H. Lee, J.Y. Moon, and S.J. Lim, Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats. Am J Nephrol, 2009. 29(3): p. 274-82.

8. Duran-Salgado, M.B., A.F. Rubio-Guerra, C.R. Unit, H.G.D. Ticoman, C. Ticoman, M.G.F. Basic, et al., Diabetic nephropathy and inflammation. World Journal of Diabetes, 2014.

9. Lim, A.K. and G.H. Tesch, Inflammation in diabetic nephropathy. Mediators Inflamm, 2012. 2012: p. 146154.

10. Van Buren, P.N. and R. Toto, Current update in the management of diabetic nephropathy. Curr Diabetes Rev, 2013. 9(1): p. 62-77.

11. Barutta, F., G. Bruno, S. Grimaldi, and G. Gruden, Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment. Endocrine, 2015. 48(3): p. 730-42.

12. Zhang, P., Y. Sun, R. Peng, W. Chen, X. Fu, L. Zhang, et al., Long non-coding RNA Rppl1 promotes inflammation and proliferation of mesangial cells in diabetic nephropathy via an interaction with Gal-3. Cell Death Dis, 2019. 10(7): p. 526.

13. Peng, W., S. Huang, L. Shen, Y. Tang, H. Li, and Y. Shi, Long noncoding RNA NONHSAG053901 promotes diabetic nephropathy via stimulating Egr-1/TGF-beta-mediated renal inflammation. J Cell Physiol, 2019. 234(10): p. 18492-18503.

14. Ma, J., N. Zhao, L. Du, and Y. Wang, Downregulation of IncRNA NEAT1 inhibits mouse mesangial cell proliferation, fibrosis, and inflammation but promotes apoptosis in diabetic nephropathy. Int J Clin Exp Pathol, 2019. 12(4): p. 1174-1183.

15. Cui, H.X., M.Y. Zhang, K. Liu, J. Liu, Z.L. Zhang, and L. Fu, LncRNA SNHG15 promotes proliferation and migration of lung cancer via targeting microRNA-211-3p. Eur Rev Med Pharmacol Sci, 2018. 22(20): p. 6838-6844.

16. Kong, Q. and M. Qiu, Long noncoding RNA SNHG15 promotes human breast cancer proliferation, migration and invasion by sponging miR-211-3p. Biochem Biophys Res Commun, 2018. 495(2): p. 1594-1600.

17. Qu, C., C. Dai, Y. Guo, R. Qin, and J. Liu, Long noncoding RNA SNHG15 serves as an oncogene and predicts poor prognosis in epithelial ovarian cancer. Onco Targets Ther, 2019. 12: p. 101-111.

18. Zhang, Y., D. Zhang, J. Lv, S. Wang, and Q. Zhang, LncRNA SNHG15 acts as an oncogene in prostate cancer by regulating miR-338-3p/FKBp1A axis. Gene, 2019. 705: p. 44-50.

19. Jiang, X., Q. Ru, P. Li, X. Ge, K. Shao, L. Xi, et al., LncRNA SNHG16 induces proliferation and fibrogenesis via modulating miR-141-3p and CCND1 in diabetic nephropathy. Gene Ther, 2020.

20. Zha, F., X. Qu, B. Tang, J. Li, Y. Wang, P. Zheng, et al., Long non-coding RNA MEG3 promotes fibrosis and inflammatory response in diabetic nephropathy via miR-181a/Egr-1/TLR4 axis.
Aging (Albany NY), 2019. 11(11): p. 3716-3730.

21. Li, M., Q. Guo, H. Cai, H. Wang, Z. Ma, and X. Zhang, miR-218 regulates diabetic nephropathy via targeting IKK-beta and modulating NK-kappaB-mediated inflammation. J Cell Physiol, 2020. 235(4): p. 3362-3371.

22. Wu, J., K. Lu, M. Zhu, X. Xie, Y. Ding, X. Shao, et al., miR-485 suppresses inflammation and proliferation of mesangial cells in an in vitro model of diabetic nephropathy by targeting NOX5. Biochem Biophys Res Commun, 2020. 521(4): p. 984-990.

23. Li, X.Y., S.S. Wang, Z. Han, F. Han, Y.P. Chang, Y. Yang, et al., Triptolide Restores Autophagy to Alleviate Diabetic Renal Fibrosis through the miR-141-3p/PTEN/Akt/mTOR Pathway. Mol Ther Nucleic Acids, 2017. 9: p. 48-56.

24. Kaur, H., A. Chien, and I. Jialal, Hyperglycemia induces Toll like receptor 4 expression and activity in mouse mesangial cells: relevance to diabetic nephropathy. Am J Physiol Renal Physiol, 2012. 303(8): p. F1145-50.

25. Sortica, D.A., D. Crispim, G.P. Zaffari, R. Friedman, and L.H. Canani, The role of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 in diabetic nephropathy. Arq Bras Endocrinol Metabol, 2011. 55(9): p. 677-85.

26. Burcelin, R., M. Serino, C. Chabo, V. Blasco-Baque, and J. Amar, Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetol, 2011. 48(4): p. 257-273.

27. Czajka, A. and A.N. Malik, Hyperglycemia induced damage to mitochondrial respiration in renal mesangial and tubular cells: Implications for diabetic nephropathy. Redox Biol, 2016. 10: p. 100-107.

28. Hallan, S. and K. Sharma, The Role of Mitochondria in Diabetic Kidney Disease. Curr Diab Rep, 2016. 16(7): p. 61.

29. Bohle, A., M. Wehrmann, O. Bogenschutz, C. Batz, C.A. Muller, and G.A. Muller, The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract, 1991. 187(2-3): p. 251-9.

30. Cheng, J., L. Cheng, Y. Tang, H. Li, W. Peng, and S. Huang, Inhibition of IncRNA Dlx6os1 decreases cell proliferation and fibrosis and increases cell apoptosis in diabetic nephropathy. Int J Clin Exp Pathol, 2018. 11(7): p. 3302-3309.

31. Li, J., X. Jiang, L. Duan, and W. Wang, Long non-coding RNA MEG3 impacts diabetic nephropathy progression through sponging miR-145. Am J Transl Res, 2019. 11(10): p. 6691-6698.

32. Yang, J., Y. Shen, X. Yang, Y. Long, S. Chen, X. Lin, et al., Silencing of long noncoding RNA XIST protects against renal interstitial fibrosis in diabetic nephropathy via microRNA-93-5p-mediated inhibition of CDKN1A. Am J Physiol Renal Physiol, 2019. 317(5): p. F1350-F1358.

33. Feng, X., J. Zhao, J. Ding, X. Shen, J. Zhou, and Z. Xu, LncRNA Blnc1 expression and its effect on renal fibrosis in diabetic nephropathy. Am J Transl Res, 2019. 11(9): p. 5664-5672.

34. Liu, Z.Z., C.Y. Zhang, L.L. Huang, and W. Liu, Elevated expression of IncRNA SNHG15 in spinal tuberculosis: preliminary results. Eur Rev Med Pharmacol Sci, 2019. 23(20): p. 9017-9024.

35. Jiang, X., M. Yu, T. Zhu, L. Lou, X. Chen, Q. Li, et al., Kcnq1ot1/miR-381-3p/ETS2 Axis Regulates Inflammation in Mouse Models of Acute Respiratory Distress Syndrome. Mol Ther Nucleic Acids, 2020. 19: p. 179-189.

36. Guo, S., Y. Chen, J. Liu, J. Yang, C. Yang, T. Zhang, et al., miR-497a-5p attenuates
lipopolysaccharide-induced inflammatory injury by targeting IRAK2. J Cell Physiol, 2019. 234(12): p. 22874-22883.

37. Xu, W., L. Zhang, Y. Geng, Y. Liu, and N. Zhang, Long noncoding RNA GASS promotes microglial inflammatory response in Parkinson’s disease by regulating NLRP3 pathway through sponging mir-223-3p. Int Immunopharmacol, 2020. 85: p. 106614.

38. Zhang, X., C.R. Huang, S. Pan, Y. Pang, Y.S. Chen, G.C. Zha, et al., Long non-coding RNA SNHG15 is a competing endogenous RNA of mir-141-3p that prevents osteoarthritis progression by upregulating BCL2L13 expression. Int Immunopharmacol, 2020. 83: p. 106425.

39. Staunton, D.E., S.D. Marlin, C. Stratowa, M.L. Dustin, and T.A. Springer, Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin superfamilies. Cell, 1988. 52(6): p. 925-33.

40. Gu, H.F., J. Ma, K.T. Gu, and K. Brismar, Association of intercellular adhesion molecule 1 (ICAM1) with diabetes and diabetic nephropathy. Front Endocrinol (Lausanne), 2012. 3: p. 179.

41. Navarro-Gonzalez, J.F., C. Mora-Fernandez, M. Muros de Fuentes, and J. Garcia-Perez, Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol, 2011. 7(6): p. 327-40.

42. Watanabe, N., K. Shikata, Y. Shikata, K. Sarai, K. Omori, R. Kodera, et al., Involvement of MAPKs in ICAM-1 expression in glomerular endothelial cells in diabetic nephropathy. Acta Med Okayama, 2011. 65(4): p. 247-57.

43. Chow, F.Y., D.J. Nikolic-Paterson, E. Ozols, R.C. Atkins, and G.H. Tesch, Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol, 2005. 16(6): p. 1711-22.

44. Altannavch, T.S., K. Roubalova, P. Kucera, and M. Andel, Effect of high glucose concentrations on expression of ELAM-1, VCAM-1 and ICAM-1 in HUVEC with and without cytokine activation. Physiol Res, 2004. 53(1): p. 77-82.

45. Park, C.W., J.H. Kim, J.H. Lee, Y.S. Kim, H.J. Ahn, Y.S. Shin, et al., High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa B-dependent. Diabetologia, 2000. 43(12): p. 1544-53.

46. Kado, S., T. Wakatsuki, M. Yamamoto, and N. Nagata, Expression of intercellular adhesion molecule-1 induced by high glucose concentrations in human aortic endothelial cells. Life Sci, 2001. 68(7): p. 727-37.

47. Omi, H., N. Okayama, M. Shimizu, M. Okouchi, S. Ito, T. Fukutomi, et al., Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells: effect of antidiabetic medicines. J Diabetes Complications, 2002. 16(3): p. 201-8.

48. Liu, R.R., J. Li, J.Y. Gong, F. Kuang, J.Y. Liu, Y.S. Zhang, et al., MicroRNA-141 regulates the expression level of ICAM-1 on endothelium to decrease myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol, 2015. 309(8): p. H1303-13.

49. Tsoyer, K., H.J. Jang, I.T. Nizamutdinova, K. Park, Y.M. Kim, H.J. Kim, et al., PTEN differentially regulates expressions of ICAM-1 and VCAM-1 through PI3K/Akt/GSK-3beta/GATA-6 signaling pathways in TNF-alpha-activated human endothelial cells. Atherosclerosis, 2010. 213(1): p. 115-21.

50. Liu, C.W., T.L. Lee, Y.C. Chen, C.J. Liang, S.H. Wang, J.H. Lue, et al., PM2.5-induced oxidative
stress increases intercellular adhesion molecule-1 expression in lung epithelial cells through the IL-6/AKT/STAT3/NF-kappaB-dependent pathway. Part Fibre Toxicol, 2018. 15(1): p. 4.

51. Yang, S.F., M.K. Chen, Y.S. Hsieh, T.T. Chung, Y.H. Hsieh, C.W. Lin, et al., Prostaglandin E2/EP1 signaling pathway enhances intercellular adhesion molecule 1 (ICAM-1) expression and cell motility in oral cancer cells. J Biol Chem, 2010. 285(39): p. 29808-16.

52. Chen, C., K. Huang, J. Hao, J. Huang, Z. Yang, F. Xiong, et al., Polydatin attenuates AGEs-induced upregulation of fibronectin and ICAM-1 in rat glomerular mesangial cells and db/db diabetic mice kidneys by inhibiting the activation of the SphK1-S1P signaling pathway. Mol Cell Endocrinol, 2016. 427: p. 45-56.

53. Zou, Y., Z. Chen, J. Li, W. Gong, L. Zhang, F. Xu, et al., Progestin and AdipoQ Receptor 3 Upregulates Fibronectin and Intercellular Adhesion Molecule-1 in Glomerular Mesangial Cells via Activating NF-kappaB Signaling Pathway Under High Glucose Conditions. Front Endocrinol (Lausanne), 2018. 9: p. 275.
Figure legends

Figure 1. Release of inflammatory factors in high-glucose (HG)-induced human glomerular mesangial cells (HGMCs) is restrained by small nucleolar RNA host gene 15 (SNHG15) knockdown. (A) The expression of SNHG15 in diabetic nephropathy (DN) tissues (n = 15) and normal tissues (n = 20) was detected by quantitative reverse-transcription PCR (qRT-PCR). ***P < 0.001 vs. normal. (B) The expression of SNHG15 in HG-stimulated HGMCs was determined by qRT-PCR. ***P < 0.001 vs. the normal glucose (NG) group. (C) The expression of SNHG15 after transfection of shRNA (sh)-SNHG15/negative control (NC) or overexpression (oe)-SNHG15/pcDNA3.1 into HG-stimulated HGMCs was detected by qRT-PCR. (D) The viability of HG-stimulated HGMCs was measured by MTT assay. (E) The levels of IL-1β, IL-6 and TNF-α in HG-stimulated HGMCs were measured by ELISA. ***P < 0.001 vs. the sh-NC group; ### P < 0.001 vs. the pcDNA3.1 group.

Figure 2. MicroRNA (MiR)-141 is the direct target of small nucleolar RNA host gene 15 (SNHG15). (A) The predicted complementary binding site of SNHG15 and miR-141. (B) The luciferase activity in human glomerular mesangial cells (HGMCs) co-transfected with pGL3-SNHG15 WT/pGL3-SNHG15 MUT and miR-141 mimics/NC was determined by dual luciferase reporter (DLR) assay. ***P < 0.001 vs. the miR-negative control (NC) group. (C) The expression of miR-141 in diabetic nephropathy (DN) tissues (n = 15) and normal tissues (n = 20) was detected by quantitative reverse-transcription PCR (qRT-PCR). ***P < 0.001 vs. normal. (D) The correlation between SNHG15 and miR-141. P < 0.0001, R² = 0.701. (E) The expression of miR-141 after transfection of shRNA (sh)-SNHG15/NC or overexpression (oe)-SNHG15/pcDNA3.1 into high-glucose (HG)-induced human glomerular mesangial cells (HGMCs) is restrained by small nucleolar RNA host gene 15 (SNHG15) knockdown. (A) The expression of SNHG15 in diabetic nephropathy (DN) tissues (n = 15) and normal tissues (n = 20) was detected by quantitative reverse-transcription PCR (qRT-PCR). ***P < 0.001 vs. normal. (B) The expression of SNHG15 in HG-stimulated HGMCs was determined by qRT-PCR. ***P < 0.001 vs. the normal glucose (NG) group. (C) The expression of SNHG15 after transfection of shRNA (sh)-SNHG15/negative control (NC) or overexpression (oe)-SNHG15/pcDNA3.1 into HG-stimulated HGMCs was detected by qRT-PCR. (D) The viability of HG-stimulated HGMCs was measured by MTT assay. (E) The levels of IL-1β, IL-6 and TNF-α in HG-stimulated HGMCs were measured by ELISA. ***P < 0.001 vs. the sh-NC group; ### P < 0.001 vs. the pcDNA3.1 group.
glomerular mesangial cells (HGMCs) was detected by qRT-PCR. ***P < 0.001 vs. the sh-NC group; ###P < 0.001 vs. the pcDNA3.1 group.

Figure 3. Overexpression of microRNA (miR)-141 declines the levels of inflammatory factors in high-glucose (HG)-induced human glomerular mesangial cells (HGMCs). (A) The expression of miR-141 in HG-stimulated HGMCs was determined by quantitative reverse-transcription PCR (qRT-PCR). ***P < 0.001 vs. the normal glucose (NG) group. (B) The expression of SNHG15 after transfection of miR-141 mimics/negative control (NC) or miR-141 inhibitor/inhibitor NC into HG-stimulated HGMCs was detected by qRT-PCR. (C) The viability of HG-stimulated HGMCs was measured by MTT assay. (D) The levels of IL-1β, IL-6 and TNF-α in HG-stimulated HGMCs were measured by ELISA. ***P < 0.001 vs. the miR-NC group; ###P < 0.001 vs. the inhibitor NC group.

Figure 4. Intercellular adhesion molecule-1 (ICAM-1) is the target gene of microRNA (miR)-141. (A) The predicted complementary binding site of ICAM-1 and miR-141. (B) The luciferase activity in human glomerular mesangial cells (HGMCs) co-transfected with pGL3-ICAM-1 WT/pGL3-ICAM-1 MUT and miR-141 mimics/negative control (NC) was determined by dual luciferase reporter (DLR) assay. ***P < 0.001 vs. the miR-NC group. (C) The protein level of ICAM-1 was measured by western blot assay. ***P < 0.001 vs. the miR-NC group; ###P < 0.001 vs. the inhibitor NC group.

Figure 5. MicroRNA (MiR)-141 diminishes the levels of inflammatory factors in high-glucose (HG)-induced human glomerular mesangial cells (HGMCs) through regulating Intercellular adhesion molecule-1 (ICAM-1). (A) The expression of ICAM-1 in HG-stimulated HGMCs was determined by quantitative
reverse-transcription PCR (qRT-PCR). ***P < 0.001 vs. the normal glucose (NG) group. (B) The protein level of ICAM-1 was measured by western blot assay. (C) The viability of HG-stimulated HGMCs was measured by MTT assay. (D) The levels of IL-1β, IL-6 and TNF-α in HG-stimulated HGMCs were measured by ELISA. ***P < 0.001 vs. the miR-negative control (NC) group; ### P < 0.001 vs. the miR-141 mimics group.

Figure 6. Small nucleolar RNA host gene 15 (SNHG15) knockdown promotes the viability and inhibits inflammatory response of high-glucose (HG)-induced human glomerular mesangial cells (HGMCs) by regulating microRNA (miR)-141/Intercellular adhesion molecule-1 (ICAM-1). (A) The protein level of ICAM-1 was measured by western blot assay. (B) The viability of HG-stimulated HGMCs was measured by MTT assay. (C) The levels of IL-1β, IL-6 and TNF-α in HG-stimulated HGMCs were measured by ELISA. ***P < 0.001 vs. the shRNA (sh)-negative control (NC) group; # P < 0.05, ## P < 0.01, ### P < 0.001 vs. the sh-SNHG15 group.
Figure A: Relative expression of SNHG15 in Normal and DN samples.

Figure B: Relative expression of SNHG15 in NG and HG conditions.

Figure C: Relative expression of SNHG15 in different treatments: Blank, sh-NC, sh-SNHG15, pcDNA3.1, oe-SNHG15.

Figure D: Cell viability (OD 450) of different treatments: sh-NC, sh-SNHG15, pcDNA3.1, oe-SNHG15.

Figure E: Relative expression of chemokines: IL-1β, IL-6, TNF-α in different treatments: sh-NC, sh-SNHG15, pcDNA3.1, oe-SNHG15.
A

SNHG15-WT: 5' ugccugccAUCCGUCAUGUU 3'
miR-141: 3' guagaaaaUGGUCUGUCACAAu 5'
SNHG15-mut: 5' ugccugccGUCCAUGAUAGAA 3'

B

Relative luciferase activity

|          | miR-NC | miR-141 mimic |
|----------|--------|--------------|
| SNHG15-WT| 1.00   | 0.99**       |
| SNHG15-MUT| 1.00   | 0.99**       |

C

Relative expression of miR-141

D

Relative expression of miR-141 vs. SNHG15

R² = 0.701
P < 0.0001

E

Relative expression of miR-141

|          | sh-NC | sh-SNHG15 | pcDNA3.1 | oe-SNHG15 |
|----------|-------|-----------|----------|-----------|
|          | 1.00  | 0.99**    | 1.00     | 0.99***   |

*** P < 0.001
A

ICAM1: 5' acAUACAUU--UCUGCCAGUGUUm 3'

miR-141: 3' ggUA--GAAUGGUCUGUCACAm 5'

ICAM1-mut: 5' acAGACAAAU--UGUGCCUCUAm 3'

B

Relative luciferase activity

|           | miR-NC | miR-141 mimics |
|-----------|--------|----------------|
| ICAM1     | 1.00   | 0.75           |
| ICAM1 mut | 1.00   | 0.80           |

***

C

Relative expression of ICAM1

|         | miR-NC | miR-141 mimics | inhibitor NC | miR-141 inhibitor |
|---------|--------|----------------|--------------|------------------|
| ICAM1   | 1.00   | 0.50           | 0.20         | 2.50             |
| β-actin | 1.00   | 0.90           | 0.80         | 1.10             |

***

####
Figure 6A β-actin

- sh-NC
- sh-SNHG15
- sh-SNHG15 + miR-141 inhibitor
- sh-SNHG15 + ce-ICAM1